A Spanish research consortium unveiled a CRISPR‑based gene‑editing approach that selectively targets tumors bearing oncogene amplifications, exploiting those amplifications as vulnerabilities to induce tumor cell death. The preclinical strategy suggests a synthetic‑lethality style application of CRISPR for cancers driven by copy‑number gains. At the Wistar Institute, scientists developed a tumor‑selective small‑molecule conjugate that links an Aurora kinase A inhibitor to a targeting moiety, enabling higher effective dosing in tumor tissue. Both developments aim to widen therapeutic windows: the CRISPR approach by leveraging tumor genomic context, and the conjugate by increasing tumor selectivity for cytotoxic payloads. Each raises translational questions about delivery, safety and regulatory pathways.